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OBJECTIVE: To observe patterns of antidepressant use
and concomitant psychotropics as an index of clinical
prescribing practice. METHODS: Among 1.6 million
members of Merck-Medco followed continuously be-
tween 1/1/96–12/31/98, we identified all patients (N 
42,510) who received a new antidepressant prescription
(defined as none within the prior 12 months) in 1997 (In-
dex AD). We observed the time between the use of other
concomitant psychotherapeutics (e.g. conventional anti-
psychotics (AP)/atypical antipsychotics (AP-A), benzodi-
azepine, anxiolytics (ANX)/buspirone (ANX-B), sedative/
hypnotics (SH) and zolipidem (SH-Z)) in the year prior
to or year after the index AD prescription. RESULTS:
14,792 (34.8%) AD patients were prescribed a concomi-
tant psychotherapeutic agent. All classes of concomitant
psychotherapeutics revealed a similar general pattern: a
steady increase in daily use in the year prior to an index
AD, a peak on the index AD date, and a tapering over the
next year. However, patients were more likely to receive
a conventional antipsychotic and anxiolytic prior to the
index AD, and an atypical antipsychotic and buspirone
after the index AD.
CONCLUSIONS: Whereas we hypothesized excessive
benzodiazepine and hypnotic usage pre- and post-index
AD, we noted lower than expected usage. We did not ex-
pect the pattern of increased atypical antipsychotic usage
on the same day or subsequent to an index AD. We spec-
ulate that continuing medical education of physicians
may be contributing to a decrease in the putative misuse
of benzodiazepines and hypnotics.
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Concomitant % of AD patients
Pre-Index 
AD (cumulative-1yr)
AP 2.28 .87
AP-A 2.36 .58
ANX 21.30 12.30
ANX-B 3.73 1.58
SH 5.73 2.98
SH-Z 8.96 4.25
Concomitant Same Day
Post-Index 
AD (cumulative-1 yr)
AP .30 1.12
AP-A .38 1.40
ANX 1.99 7.00
ANX-B .36 1.79
SH .37 2.37
SH-Z .75 3.97
BACKGROUND: The California Medicaid program
(Medi-Cal) added fluoxetine and paroxetine to its formu-
lary in May 1996. OBJECTIVES: This study evaluated
the impact of this policy change on the number of pa-
tients seeking treatment, treatment completion rates and
the cost of treating depressed patients. METHODS: All
patients with a recorded diagnosis of major depression
(MDD) between 09/01/1994 and 12/31/1997 were se-
lected from the Medi-Cal paid claims system. Completed
therapy required 180 days of uninterrupted therapy at an
adequate dose as estimated from drug claims. Multivari-
ate statistical models of treatment completion and direct
health care costs were estimated. RESULTS: The policy
change resulted in an immediate increase in the number
of new antidepressant drug therapy episodes initiated per
month (woodwork effect), but only for the newly added
drugs. The prior use profile of treated patients exhibited
a significant time trend toward higher prior use and com-
pleted therapy rates decreased for all products. Patients
treated initially with fluoxetine and sertraline were signif-
icantly more likely to complete therapy than TCA pa-
tients (odds ratios: 4.73 before change, 2.10 after for flu-
oxetine; 2.15 and 1.24 for sertaline, respectively).
Completion rates for paroxetine were not statistically
different from TCAs (odds ratios: 1.27, P  0.3147 be-
fore and 1.017, P  0.3943 after). Completed therapy
was associated with reductions in ambulatory care costs
in both periods. However, increased drug costs com-
pletely offset these savings after the formulary change.
CONCLUSION: The change in Medi-Cal formulary pol-
icy adding fluoxetine and paroxetine may have provided
new treatment options for more severely ill, refractory
patients that may have resulted in a modest increase in
costs.
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Osteoporosis affects over 28 million Americans, causing
over $13.8 billion in healthcare costs annually. Aging of
the population is expected to increase the national bur-
den of osteoporosis, though little is known about state
level impacts. In Florida, there is a large and growing at-
risk population (6.2 million age 45 and 2.7 million age
65). In 1998, there were 25,000, 4500, 1600 and
12,500 hip, vertebral, forearm/wrist and other fracture
hospitalizations, respectively. OBJECTIVE: To predict
the costs of osteoporosis in Florida over the next decade.
METHODS: Inpatient costs were estimated from Florida
hospital discharge data and primary and long-term care
costs were obtained from published national estimates.
Costs of osteoporosis for women age 50–100 were pre-
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dicted using a Markov model, which tracked cohort
movements across fracture outcome states. We ran 50
consecutive cohorts, starting each year of age 50 through
99, each with a 10-year follow up. Average cost at each
individual patient age was adjusted by osteoporosis attri-
bution rates; then the population of women within ages
50–100 was multiplied by average cost to determine total
cost by age, within each year (2000–2009). Because frac-
ture incidence rates were unavailable, costs of other frac-
tures and total costs of osteoporosis in males were esti-
mated by multiplying base year costs by the respective
population increases over time. RESULTS: Discounted
costs of osteoporosis were over $1 billion in 2000 and in-
creased to $1.21 billion (21%) by 2009. The greatest cost
increases were for age groups 50–64 and 85. Total cost
for the decade exceeded $11.1 billion. CONCLUSIONS:
Osteoporosis is predicted to have substantial and increas-
ing impacts on Florida’s healthcare resources. This infor-
mation may contribute to health policy discussions in
Florida.
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Since osteoporosis is a silent disease until fracture occurs,
identification of patients with a high lifetime risk of fur-
ther developing this disorder, using bone densitometry, is
widely recognized as the gold standard diagnostic proce-
dure. Nonetheless, measuring Bone Mineral Density (BMD)
for the whole population has proved to be either unfeasi-
ble and/or cost inefficient as public health resources are
limited. Therefore several attempts have been made to
develop tools aiming at selecting persons with low BMD
who should be referred for bone densitometry. The Sim-
ple Calculated Osteoporosis Risk Estimation (SCORE),
has been just designed for this purpose. OBJECTIVE:
The main objective of our study was to assess the poten-
tial efficiency of this instrument for a more rational use
of bone densitometry by excluding subjects who are un-
likely to need such a procedure. Our sample consisted of
4035 white women aged at least 45 years, recruited ret-
rospectively from a Belgian outpatient osteoporosis cen-
ter. BMD measures, using DEXA technology were col-
lected at the regions of the lumbar spine (L2-L4), the
femoral neck and the total hip. METHOD: At, at least
one of these sites, 47% of our sample had a low BMD
(defined as t-score  2 SD) and more than 32 % were
found osteoporotic, according to WHO definition
(t-score  2.5 SD). At the recommended SCORE cut-
point of 6, 18% of the patients would not be recom-
mended for densitometry. Among those, 10.9% were
misclassified as they did have osteoporosis at, at least one
of the considered sites. Considering each site separately,
the negative predictive errors of SCORE, when failing to
detect osteoporosis, were only 1% for the total hip, 3.2%
for the femoral neck and 8.8%for the lumbar spine.
CONCLUSIONS: We conclude that although the overall
accuracy of SCORE had demonstrated to be quite poor
as a diagnostic tool, from a resource allocation stand
point, this instrument could be used with relative confi-
dence to exclude patients who do not need a BMD mea-
surement, opening the perspective of substantial savings
in comparison to a mass screening strategy.
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Osteoporosis is a major public health problem in post-
menopausal women. Identifying patients at risk of devel-
oping an osteoporosis related fracture remains one of the
challenges of the next decades. Although it is widely rec-
ognized that the “gold standard” procedure for os-
teoporosis diagnosis is bone densitometry, economic is-
sues or availability of the densitometers may prevent its
use under a mass screening scenario. A risk assessment
instrument, the Simple Calculated Osteoporosis Risk Es-
timation (SCORE), has been developed to be used for se-
lecting women likely to have low bone mass density
(BMD) for referring for bone densitometry. Low BMD
was defined as 2 standard deviations or more below the
mean of young healthy adult. The promises shown by the
original validation of SCORE have to be further tested
on different populations. A couple of published studies
did not reach the same level of satisfaction. OBJECTIVE:
The aim of our study is to evaluate this prescreening tool
in a large sample of Caucasian women, at different levels
of BMD and at various sites of measurement. METHOD:
We gathered medical data on 4035 patients aged 45
years or more, either consulting spontaneously or re-
ferred for a BMD measurement to an outpatient os-
teoporosis center located in Liege, Belgium. BMD mea-
sures, using DEXA technology, were listed at the hip
(both total and neck) and the lumbar spine (L2-L4). RE-
SULTS: More than 47% of our sample presented with
